Operation Warp Speed (OWS), the Trump administration's bold effort to deliver at least 300 million doses of a safe and effective coronavirus vaccine by January, took another expensive step forward. On Friday, Sanofi (NASDAQ: SNY) and GlaxoSmithKline (NYSE: GSK) signed a vaccine-supply deal with the U.S. government worth up to $2.1 billion to help the collaboration partners scale up manufacturing of a vaccine candidate -- before there are clinical-trial results that prove it safely prevents SARS-CoV-2, the virus that causes COVID-19, from spreading.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,